ImmunoCellular Plans Job Cuts in Shift to Stem-to-T-Cell Program – Genetic Engineering & Biotechnology News (press release)
The Herald of Finance |
ImmunoCellular Plans Job Cuts in Shift to Stem-to-T–Cell Program
Genetic Engineering & Biotechnology News (press release) The company says that Stem-to-T–Cell offers a more gradual and measured release of killer T cells than chimeric antigen receptor T–cell (CAR-T) technologies, thus avoiding the limited response, and even toxicity, associated with some CAR-T treatments. ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy |
